In This Article:
In the midst of a busy earnings season, global markets have been experiencing notable fluctuations, with major indices like the Nasdaq Composite and S&P MidCap 400 reaching record highs before facing sharp declines. Amid this backdrop, growth stocks have generally underperformed compared to value shares, highlighting the importance of insider ownership as a potential indicator of confidence and alignment with shareholders' interests. In such volatile times, companies with significant insider investment may offer reassurance to investors looking for strong commitment from those at the helm.
Top 10 Growth Companies With High Insider Ownership
Name | Insider Ownership | Earnings Growth |
Lavvi Empreendimentos Imobiliários (BOVESPA:LAVV3) | 17.3% | 21.1% |
Medley (TSE:4480) | 34% | 30.4% |
Seojin SystemLtd (KOSDAQ:A178320) | 30.7% | 49.1% |
Pharma Mar (BME:PHM) | 11.8% | 56.4% |
Findi (ASX:FND) | 34.8% | 64.8% |
Credo Technology Group Holding (NasdaqGS:CRDO) | 13.9% | 95% |
Alkami Technology (NasdaqGS:ALKT) | 11.2% | 98.6% |
Plenti Group (ASX:PLT) | 12.8% | 107.6% |
EHang Holdings (NasdaqGM:EH) | 32.8% | 81.4% |
UTI (KOSDAQ:A179900) | 33.1% | 134.6% |
Underneath we present a selection of stocks filtered out by our screen.
iFAST
Simply Wall St Growth Rating: ★★★★☆☆
Overview: iFAST Corporation Ltd. offers investment products and services across Singapore, Hong Kong, Malaysia, China, and the United Kingdom with a market capitalization of SGD2.14 billion.
Operations: The company generates revenue from its investment products and services across multiple regions, including Singapore, Hong Kong, Malaysia, China, and the United Kingdom.
Insider Ownership: 28.7%
Return On Equity Forecast: 27% (2027 estimate)
iFAST Corporation Ltd. demonstrates significant growth potential with recent earnings showing a net income increase to S$16.81 million in Q3 2024 from S$8.52 million the previous year, reflecting a strong upward trajectory. Despite revenue growth forecasts of 9.5% annually, which is slower than some benchmarks, it still surpasses the Singapore market average of 3.7%. The company's high insider ownership aligns with its robust earnings performance and strategic board changes enhance governance stability.
-
Click to explore a detailed breakdown of our findings in iFAST's earnings growth report.
-
Upon reviewing our latest valuation report, iFAST's share price might be too optimistic.
Zhejiang Jolly PharmaceuticalLTD
Simply Wall St Growth Rating: ★★★★★☆
Overview: Zhejiang Jolly Pharmaceutical Co., LTD is involved in the research, production, and marketing of Chinese medicinal products both domestically in China and internationally, with a market cap of CN¥10.92 billion.